5-Amino-1MQ

Overview

5-Amino-1MQ is a small heterocyclic molecule (not a peptide) that acts as a selective, membrane-permeable inhibitor of nicotinamide N-methyltransferase (NNMT). It is under preclinical investigation for obesity and non-alcoholic fatty liver disease. It is not FDA-approved and has not completed human clinical trials; it is commonly tracked alongside peptides because grey-market vendors sell it for metabolic protocols.

Mechanism of Action

NNMT methylates nicotinamide using S-adenosylmethionine (SAM), producing 1-methylnicotinamide (MNA) and depleting both the NAD+ salvage precursor pool and the SAM methyl donor pool. By inhibiting NNMT, 5-Amino-1MQ lowers intracellular MNA and raises intracellular NAD+ and SAM. In adipocytes this has been reported to suppress lipogenesis and reduce adipocyte size in rodent models. Downstream links to SIRT1 activation and fat oxidation are frequently proposed but are not firmly established in vivo.

Research Summary

Neelakantan et al. (2018, Biochem Pharmacol, PMID 29155147) reported that 5-Amino-1MQ and related selective, membrane-permeable methylquinolinium NNMT inhibitors reversed high-fat-diet-induced obesity in mice, reducing body weight, white adipose mass, adipocyte size, and plasma cholesterol without changing food intake. A separate NNMT inhibitor program (Kannt et al., 2018, Sci Rep, PMID 29483571, JBSNF-000088) produced similar metabolic effects in rodents. Dimet-Wiley et al. (2022, Sci Rep, PMID 35013352) reported microbiome changes with NNMT inhibition plus low-fat diet in DIO mice, and Babula et al. (2024, Diabetes Obes Metab, PMID 39161060) showed 5A1MQ dose-dependently limited weight and fat gain and reduced NAFLD-like liver pathology in DIO mice. No human clinical trials of 5-Amino-1MQ have been completed or published as of 2026; grey-market oral protocols are not clinically validated.

Vendors selling 5-Amino-1MQ

Scored vendors carrying 5-Amino-1MQ, ranked by trust grade. Grades are computed from indexed Certificates of Analysis. Full $/mg pricing is on the comparison page.

Prescribers who offer 5-Amino-1MQ

15 prescribers in our directory work with 5-Amino-1MQ, each confirmed from their own website. Peptides like 5-Amino-1MQ require a prescription from a licensed provider.

Reported Side Effects

• No controlled human safety data — all adverse-effect information is anecdotal or theoretical
• Anecdotal reports of nausea and mild GI upset
• Theoretical: NNMT inhibition raises SAM, which could shift methylation balance and affect neurotransmitter or catecholamine metabolism
• Rodent studies did not report overt toxicity at effective doses

Compare 5-Amino-1MQ with Others

Research References

• Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice (Neelakantan et al., Biochem Pharmacol, PMID 29155147) (2018)
• A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disorders (Kannt et al., Sci Rep, PMID 29483571) (2018)
• Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction (Babula et al., Diabetes Obes Metab, PMID 39161060) (2024)

Frequently asked questions

Has 5-Amino-1MQ been independently lab-tested?

Disclosed Labs has collected 84 Certificates of Analysis (COA) for 5-Amino-1MQ from 12 independent testing labs. 25 vendors have submitted material for testing. Products average 99.6% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/5-amino-1mq/testing.

What is the average purity of 5-Amino-1MQ on the market?

Based on 84 COAs analyzed by Disclosed Labs, 5-Amino-1MQ products average 99.6% (±0.6%) tested purity. Individual vendor results vary; see per-vendor COA data at https://www.disclosedlabs.com/peptides/5-amino-1mq/coas.

Which labs have tested 5-Amino-1MQ?

Independent labs that have tested 5-Amino-1MQ include: ILS Labs (Grade A), Ethos Analytics (Grade B). Full lab credibility grades and profiles are at https://www.disclosedlabs.com/labs.

Where can researchers source 5-Amino-1MQ?

8 vendors with Disclosed Labs trust grades currently list 5-Amino-1MQ, including Glacier Aminos, Ion Peptide, Voltera Sciences. Compare live prices and lab-verified COAs at https://www.disclosedlabs.com/prices/5-amino-1mq.

Which prescribers offer 5-Amino-1MQ with a prescription?

15 prescribers in the Disclosed Labs directory work with 5-Amino-1MQ, each confirmed from their own website. 5-Amino-1MQ requires a prescription from a licensed provider. Browse them at https://www.disclosedlabs.com/prescribers?peptide=5-Amino-1MQ.

How does 5-Amino-1MQ work?

NNMT methylates nicotinamide using S-adenosylmethionine (SAM), producing 1-methylnicotinamide (MNA) and depleting both the NAD+ salvage precursor pool and the SAM methyl donor pool. By inhibiting NNMT, 5-Amino-1MQ lowers intracellular MNA and raises intracellular NAD+ and SAM. In adipocytes this has been reported to suppress lipogenesis and reduce adipocyte size in rodent models. Downstream links to SIRT1 activation and fat oxidation are frequently proposed but are not firmly established in vivo.

What does the research say about 5-Amino-1MQ?

Neelakantan et al. (2018, Biochem Pharmacol, PMID 29155147) reported that 5-Amino-1MQ and related selective, membrane-permeable methylquinolinium NNMT inhibitors reversed high-fat-diet-induced obesity in mice, reducing body weight, white adipose mass, adipocyte size, and plasma cholesterol without changing food intake. A separate NNMT inhibitor program (Kannt et al., 2018, Sci Rep, PMID 29483571, JBSNF-000088) produced similar metabolic effects in rodents. Dimet-Wiley et al. (2022, Sci Rep, PMID 35013352) reported microbiome changes with NNMT inhibition plus low-fat diet in DIO mice, and Babula et al. (2024, Diabetes Obes Metab, PMID 39161060) showed 5A1MQ dose-dependently limited weight and fat gain and reduced NAFLD-like liver pathology in DIO mice. No human clinical trials of 5-Amino-1MQ have been completed or published as of 2026; grey-market oral protocols are not clinically validated.